ReviewCNS drugs2014
Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity.
Review in CNS drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.European journal of medical research · 2022Pooled it
- The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis.The journal of headache and pain · 2017Pooled it
- The Neuropeptide α-Calcitonin Gene-Related Peptide as the Mediator of Beneficial Effects of Exercise in the Cardiovascular System.Frontiers in physiology · 2022Review
- Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Québec, Eastern Canada.Clinical drug investigation · 2021Article
- Can Monoclonal Antibodies against CGRP Offer New Treatment Options for Type 2 Diabetes?Journal of diabetes and clinical research · 2020Article
- Traditional and Novel Migraine Therapy in the Aging Population.Current pain and headache reports · 2019Review
- From LBR-101 to Fremanezumab for Migraine.CNS drugs · 2018Review
- CGRP receptor antagonist activity of olcegepant depends on the signalling pathway measured.Cephalalgia : an international journal of headache · 2018Article
- Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.Drugs · 2018Review
- Anti-CGRP monoclonal antibodies in migraine: current perspectives.Internal and emergency medicine · 2016Review
- Can aging be 'drugged'?Nature medicine · 2015Review
- CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.British journal of clinical pharmacology · 2015Article
- Taking the headache out of migraine.Neurology. Clinical practice · 2015Article
- Targeting CGRP: A New Era for Migraine Treatment.CNS drugs · 2015Review
- A second trigeminal CGRP receptor: function and expression of the AMY1 receptor.Annals of clinical and translational neurology · 2015Article
- Therapeutic antibodies against CGRP or its receptor.British journal of clinical pharmacology · 2015Review
- CGRP mechanism antagonists and migraine management.Current neurology and neuroscience reports · 2015Review
- Behavioral effects and mechanisms of migraine pathogenesis following estradiol exposure in a multibehavioral model of migraine in rat.Experimental neurology · 2015Article
- Experimental inflammation following dural application of complete Freund's adjuvant or inflammatory soup does not alter brain and trigeminal microvascular passage.The journal of headache and pain · 2015Article
- Calcitonin gene-related peptide: physiology and pathophysiology.Physiological reviews · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calcitonin gene-related peptide (CGRP) is a well-studied neuropeptide of relevance for migraine pathophysiology. Jugular levels of CGRP are increased during migraine attacks, and intravenous CGRP administration induces migraine-like headache in most individuals with migraine. Several CGRP receptor antagonists (CGRP-RAs) were shown to be effective for the acute treatment of migraine, validating the target for the treatment of migraine. However, for a number of reasons, including issues of liver toxicity with chronic use, the development of CGRP-RAs has yet to produce a viable clinical therapeutic. Development of monoclonal antibodies (mAbs) targeting the CGRP pathway is an alternative approach that should avoid many of the issues seen with CGRP-RAs. The exquisite target specificity, prolonged half-lives, and reduced potential for hepatotoxicity and drug-drug interactions make mAbs suitable for the preventive treatment of migraine headaches. This manuscript provides an overview of the role of CGRP in the pathophysiology of migraine, followed by a review of the clinical development of CGRP-RAs. Some basic concepts on antibodies are then discussed along with the publicly disclosed information on the development of mAbs targeting the CGRP pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.